Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 118

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Asthma

Not recruiting

Study on the Effects of Povorcitinib for Adults with Moderate to Severe Asthma Not Well Controlled

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not recruiting

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Uveitis

Not recruiting

Study on the Effectiveness of Baricitinib for Patients with Refractory Non-Infectious Uveitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire Rouen

Immune thrombocytopenia

Not recruiting

Study on Aspirin (D,L-Lysine Acetylsalicylate) for Patients with Immune Thrombocytopenia and Cardiovascular Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:D,L-Lysine Acetylsalicylate
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of GSK3915393 for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSK3915393
  • Sponsor:Glaxosmithkline Research & Development Limited

Immune thrombocytopenia

Not recruiting

Study on the Safety and Efficacy of PF-06835375 and Diphenhydramine Hydrochloride for Adults with Moderate to Severe Primary Immune Thrombocytopenia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:PF-06835375
  • Sponsor:Pfizer Inc.

Asthma

Not recruiting

Study on Tiotropium for Preventing Severe Asthma Attacks in Preschool Children with Uncontrolled Asthma

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tiotropium Bromide Monohydrate
  • Sponsor:Goethe University Frankfurt

Psoriasis

Not recruiting

Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Advanced systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide
  • Sponsor:Cogent Biosciences Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.